Now featuring an autosampler accessory that enables the automatic pipetting of samples and automatic start of the run, the Chorus TRIO multiparametric system consolidates infectious diseases and autoimmunity tests on a single system.
The Identi-System Bar-Code Concept ensures the elimination of human errors in the preanalytical phase. Results are reported early, reducing turn-around time and it is possible to combine any kind of test in the same run. The minimal manual operation consists of just 3 steps: dispensing the serum into the device; placing the device in the instrument and simply pressing RUN as the instrument is programmed by the device’s bar-code label.
The single test device contains all the reagents necessary to perform the assay; there are no hidden costs or waste of reagents. A master curve procedure with 1-point calibrator is included in the kit. Packaging comes in sets of 36 or 12 devices according to the type of test. The random access instrument has a capacity of up to 30 different assays per run and may be operated in batch mode. Other features include touch-screen LCD, internal bar-code reader, built-in thermal printer and a multi-wavelength photometer (450, 650 nm). The instrument provides storage of all data of the last 20 sessions as well as a bidirectional connection to a host computer (RS-232 serial port). The autosampler accessory takes up to 30 primary tubes on board with disposable tips and incorporates an internal bar-code reader. Its compact design allows it to upgrade the Chorus instrument with no extra room required. 
Read more

Streptococcus pneumoniae is the leading cause of community-acquired pneumonia and Legionella pneumophila causes costly hospital and ICU admissions. It is difficult to clinically distinguish between the two bacteria and due to different treatment of the diseases, guidelines recommend double testing.
The ImmuView Antigen test makes it now possible to readily distinguish between both microorganisms in patients with presumed infection, allowing clinicians to initiate the correct antibiotic treatment. It is the only rapid test that identifies both Streptococcus pneumoniae and Legionella pneumophila in one single test for urine and CSF samples. ImmuView is very simple to use, does not require any special equipment, and provides a result in just 15 minutes. In fact, in only 3 simple steps, it determines whether the patient has a double infection, a S. pneumoniae infection, a Legionella infection, or none of these.  

Read more

Cardiovascular disease caused by atherosclerosis is the leading cause of morbidity and mortality in Western countries. Atherosclerosis involves the hardening and narrowing of vessels in the systemic system. If the build-up increases, plaque rupturing may occur which may lead to myocardial infarction.
The mission of the National Lipid Association (NLA) “is to enhance the practice of lipid management in clinical medicine” as the current lipid testing panel consists of LDL-C, HDL-C and triglycerides. These traditional tests only detect approximately 20% of all coronary artery disease patients.  Advanced lipid testing is recommended to optimise patient treatment.
Randox offer a range of niche and superior performance lipid assays including sdLDL-C and Lp(a) to extend your lipid profile.
 
For more information go to: https://www.randox.com/lipid-testing-panel/
Read more

RPS Diagnostics recently announced an updated CE mark of its FebriDx test, clearing the way for its immediate launch in the European Union and all countries recognizing the CE mark. FebriDx is a rapid, accurate, and simple to use point-of-care test that provides clinicians with a 10-minute assessment of the body’s immune response to an acute respiratory infection (ARI) directly from a fingerstick blood sample. The single use, disposable test identifies patients who have a clinically significant underlying infection and aids in the differentiation of viral and bacterial ARIs through the rapid detection of both Myxovirus resistance protein A (MxA) and C-reactive protein (CRP). MxA is an intracellular protein that becomes elevated in the presence of acute viral infection and CRP is a nonspecific inflammatory protein that is elevated in the presence of any clinically significant infection. Thus, unlike a standalone CRP test, MxA confers specificity to the test through the combined interpretation of the results.
The updated FebriDx test incorporates an all-in-one plastic housing technology that includes a built-in safety lancet, blood collection and delivery system, and integrated push button buffer delivery feature, which together, improve test convenience. The FebriDx test requires no additional equipment to perform or to interpret results. Through comprehensive analytical testing as well as a multicentre precision and reproducibility study, RPS Diagnostics successfully demonstrated equivalency to the previously CE-marked version of the product.
The timely FebriDx test results enable clinicians to formulate a targeted clinical management and therapeutic decision plan during the initial patient encounter. Antibiotic misuse is a complex global problem that leads to antibiotic resistance, avoidable adverse events, and contributes to rising healthcare costs, largely driven by diagnostic uncertainty and patient pressure. More than 50% of all antibiotic prescriptions are unnecessary and are generated in the outpatient primary and urgent care setting. In a recent study in the United Kingdom, FebriDx was shown to alter clinical management decisions in 48% of patients tested, and to reduce unnecessary antibiotic prescriptions by 80%. Each day that goes by without the implementation of a cost-effective solution is exacerbating the current global antibiotic crisis.
It is equally important not to miss treating an underlying bacterial infection as it is withholding unnecessary antibiotics from patients with clinically insignificant or viral infection. While most research and investment over the past decade has focused on rapid molecular testing to identify specific pathogens, FebriDx utilizes the body’s own immune system to provide a broad, fast, accurate, and cost-effective method to identify patients who may benefit from appropriate antibiotic therapy.

Read more